This study is testing a new drug called KTX-2001 for men with metastatic castration-resistant prostate cancer (mCRPC). This is prostate cancer that has spread to other parts of the body and is no longer responding to standard hormone therapy. Researchers want to see if KTX-2001 is safe and how it works, both by itself and when combined with another approved prostate cancer drug called darolutamide (NUBEQA®). The main goal is to find the highest dose of KTX-2001 that can be given safely. You might be able to join if you are a man aged 18 or older with mCRPC and meet other health requirements. The study is currently recruiting about 144 participants.

Study design

This is an open-label Phase 1 study, meaning both you and the study team will know which treatment you are receiving. It plans to enroll 144 participants.

What's involved

Participants will receive increasing doses of KTX-2001, either alone or in combination with darolutamide (NUBEQA®).

Compensation

Not stated in the trial record.

Follow-up

The primary safety measure is assessed at 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.